Advertisement


Daniel J. Ma, MD, on HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Comparing Longer and Shorter Courses of Radiotherapy

2021 ASTRO Annual Meeting

Advertisement

Daniel J. Ma, MD, of the Mayo Clinic Alix School of Medicine, discusses results from a phase III study of patients with HPV-associated oropharyngeal squamous cell carcinoma. Comparing a 2-week course of de-escalated adjuvant radiation therapy with the standard 6-week course, investigators found that the shorter treatment appeared to have less toxicity, higher quality of life, and similar disease control as the longer standard-of-care treatment (Abstract LBA1).



Related Videos

Prostate Cancer

Amar U. Kishan, MD, on Prostate Cancer: Impact of Androgen-Deprivation Therapy With Radiotherapy

Amar U. Kishan, MD, of the University of California, Los Angeles, discusses findings from a meta-analysis of clinical trials in patients with localized prostate cancer. The phase III results suggest that the use of androgen-deprivation therapy (ADT) or prolonged adjuvant ADT with radiotherapy may benefit patients with localized prostate cancer. Further biomarkers are needed to better personalize treatment intensification (Abstract 8).

Head and Neck Cancer

Shauna Campbell, DO, on Head and Neck Cancer: Toxicity Associated With Hypofractionated IMRT

Shauna Campbell, DO, of Cleveland Clinic, discusses results from her study that showed hypofractionated intensity-modulated radiation therapy (H-IMRT) in the definitive or postoperative treatment of head and neck cancers using ≥ 50 Gy in 20 fractions appears to be safe and well tolerated with modest toxicity. Dr. Campbell suggests that prospective studies comparing the safety and efficacy of H-IMRT with those of conventionally fractionated IMRT are warranted (Abstract 2313).

Issues in Oncology

Daniel F. Hayes, MD, on Liquid Biopsies to Detect and Monitor Oligometastases

Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center, discusses whether liquid biopsies can provide insight into the challenge of curing metastatic breast and possibly other cancers, how oligometastases are similar to a primary cancer, and why some kinds of local therapy for widespread disease might improve survival and lead to a cure.

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.

CNS Cancers

Erin Murphy, MD, on Low-Grade Glioma: Neurocognitive Function Following Treatment

Erin Murphy, MD, of Cleveland Clinic, discusses new data that show no apparent difference in cognitive performance up to 2 years post-treatment among adults with low-grade glioma who were treated with concurrent radiotherapy and temozolomide (Abstract 3258).

Advertisement

Advertisement



Advertisement